In a groundbreaking study published in the prestigious journal Cancer Research on April 22, 2026, researchers at St. Jude Children’s Research Hospital have unveiled novel insights into the regulation of the notoriously “undruggable” MYC oncogene in pediatric medulloblastoma, specifically the high-risk Group 3 subtype (G3-MB). This subtype of brain tumor, which disproportionately affects children, is characterized by aggressive growth fueled by MYC overexpression. Despite MYC’s critical role in tumorigenesis, therapeutic strategies have been thwarted by the protein’s structural complexity, which lacks conventional drug-binding pockets. The new research elucidates a hitherto unknown mechanism underlying MYC gene amplification and regulation, setting the stage for targeted interventions.
G3-MB presents a formidable challenge in pediatric oncology due to its poor prognosis and resistance to current treatment modalities. A key driver of this malignancy is the overexpression of MYC, an oncogene that orchestrates cellular processes promoting rapid proliferation and tumor aggressiveness. Unlike typical gene amplifications residing within chromosomes, MYC is often amplified on extrachromosomal DNA (ecDNA) in these tumors. EcDNA consists of circular DNA elements detached from chromosomes, which can replicate independently, resulting in variable gene copy numbers. This dynamic genomic structure confers a formidable adaptability to cancer cells, enabling sustained high-level MYC expression that drives malignant progression.
The St. Jude team employed a combination of cutting-edge genomic techniques, including three-dimensional genome mapping, chromatin profiling, and CRISPR-based functional screens, to interrogate the regulatory landscape governing MYC expression on ecDNA. Their investigations identified a crucial enhancer element within the ecDNA, termed ecMYC E1, that exerts strong control over MYC transcription. Enhancers are segments of DNA that facilitate gene activation by physically interacting with promoter regions, acting as molecular switches that modulate gene output. This discovery revealed a previously unrecognized regulatory circuit uniquely embedded within the extrachromosomal genetic architecture of G3-MB tumors.
What makes this finding particularly significant is that ecMYC E1 is highly active and exclusive to tumor cells harboring extrachromosomal MYC amplification, rendering it a promising therapeutic target. Functional interrogation using brain tumor organoid models—three-dimensional cultures that recapitulate the histological and molecular features of patient tumors—demonstrated that silencing this enhancer markedly reduced MYC transcription. This reduction in oncogenic expression translates to a potential strategy to curb tumor growth while sparing normal tissues. These organoid models retain the genetic heterogeneity of the original tumors, offering an unparalleled platform to study ecDNA-mediated oncogene regulation in a physiologically relevant context.
Despite the promising results, the researchers discovered a remarkable adaptive mechanism employed by cancer cells in response to ecMYC E1 inhibition. Initially, suppressing the enhancer led to diminished MYC levels; however, tumor cells counteracted this effect by increasing the copy number of MYC-carrying ecDNA. This ecDNA amplification restored oncogene expression, revealing an intrinsic resilience powered by the unique replication capability of extrachromosomal elements. Intriguingly, this adaptive response was absent in tumors where MYC amplification is integrated within chromosomes, underscoring the distinct biology of ecDNA-driven cancers.
To address this obstacle, the research team proposes a combinatorial therapeutic strategy. Enhancer silencing could be paired with agents that hinder the increase in ecDNA copy number, such as checkpoint kinase 1 (CHK1) inhibitors. CHK1 plays a key role in DNA replication and cell cycle regulation, and its inhibition could prevent the compensatory ecDNA amplification, thereby enhancing treatment efficacy. This dual-pronged approach targets both the regulatory circuitry and the resilient genomic architecture, potentially overcoming tumor resistance mechanisms.
The implications of these findings extend beyond medulloblastoma. Approximately 28% of cancers feature oncogene amplification on ecDNA, suggesting a broader applicability for therapies targeting ecDNA-associated enhancers. However, MYC’s intractable structure and central oncogenic role have historically stymied efforts to develop direct inhibitors. This study marks a conceptual shift, focusing on the regulatory elements that govern MYC expression rather than the protein itself. By exploiting the unique vulnerabilities of ecDNA in tumor cells, new treatment avenues may emerge for a spectrum of high-risk malignancies driven by MYC.
Key to this research was the integration of multi-dimensional genomic technologies with innovative functional assays. The 3D genome mapping techniques allowed visualization of physical interactions between enhancers and promoters within the spatial organization of the nucleus. Chromatin profiling illuminated the epigenetic landscape defining active regulatory elements, while CRISPR-based screens enabled functional validation by selectively silencing candidate enhancers. Together, these methodologies provided a comprehensive understanding of how ecDNA confers regulatory autonomy to MYC, a phenomenon absent in chromosomally encoded genes.
The study was spearheaded by Dr. Martine Roussel, a prominent figure in tumor cell biology at St. Jude, with doctoral candidate Jake Friske playing a pivotal role in executing and interpreting the experimental findings. The collaboration incorporated expertise across genetics, molecular biology, and bioinformatics, reflecting the multidisciplinary nature of contemporary cancer research. The work was supported by grants from the National Cancer Institute, American Cancer Society, Broad Institute’s Pediatric Cancer Dependencies Accelerator, and other partners, highlighting the critical need for investment in pediatric cancer science.
Moreover, the study’s use of brain tumor organoids represents a significant advance in modeling tumor biology. These organoid systems simulate tumor microenvironments and preserve genetic diversity, providing a more faithful representation of tumor behavior than traditional cell lines. This fidelity enabled detailed studies of enhancer function and resistance mechanisms in a controlled but biologically relevant setting. The findings underscore the value of such models in preclinical research and drug development pipelines.
This research not only broadens our understanding of MYC regulation but also exemplifies the adaptive complexity of cancer genomes. EcDNA offers tumors a genomic plasticity that facilitates rapid evolution under therapeutic pressure. By targeting both the regulatory elements and replication mechanisms of ecDNA, future treatments may effectively outmaneuver tumor adaptability, providing hope for improved outcomes in children afflicted with these devastating brain tumors.
In conclusion, the identification of the ecMYC E1 enhancer on extrachromosomal DNA represents a paradigm shift in targeting MYC-driven pediatric medulloblastoma. This enhancer acts as a linchpin in sustaining oncogenic MYC expression, and its inhibition, combined with blockade of ecDNA amplification, holds promise for refined, less toxic therapeutic strategies. As the scientific community continues to unravel the complexities of ecDNA biology, the strategies illuminated by this landmark study may pave the way for innovative interventions against some of the most intractable pediatric cancers.
Subject of Research: Regulatory mechanisms of MYC oncogene expression in pediatric Group 3 medulloblastoma and novel therapeutic targets on extrachromosomal DNA.
Article Title: Enhancer provides a potential target for ‘undruggable’ MYC in pediatric medulloblastoma.
News Publication Date: April 22, 2026.
Web References:
St. Jude Children’s Research Hospital: https://www.stjude.org/
Article DOI: http://dx.doi.org/10.1158/0008-5472.CAN-25-4691
Image Credits: St. Jude Children’s Research
Keywords: Medulloblastoma, Oncogenes, MYC, Extrachromosomal DNA, ecDNA, Enhancer, Chromatin profiling, CRISPR screening, Pediatric brain tumors, Tumor organoids, Cancer genomics, Therapeutic resistance
Tags: cancer epigenetics and enhancersextrachromosomal DNA in tumorsGroup 3 medulloblastoma researchhigh-risk pediatric brain tumorsMYC gene amplification mechanismsMYC oncogene targetingMYC-driven tumor aggressivenessnovel cancer therapeutic targetspediatric medulloblastoma treatmentpediatric oncology drug resistanceSt. Jude medulloblastoma studyundruggable MYC in cancer
